New generation anticonvulsants for the treatment of epilepsy in children.
In the last 12 years, 10 new anticonvulsants have been approved by the U.S. Food and Drug Administration and, as a result, the treatment options for children and adults with epilepsy have been expanded considerably. These new generation antiepileptic drugs offer equal efficacy with improved tolerability, pharmacokinetic properties, and side effect profiles compared with the traditional drugs. With many new medications available, the clinician treating children with epilepsy must be well versed in the application of these drugs to their patient population. This manuscript will review the indications, mechanism of action, pharmacokinetics, adverse effects, and dosing of the new generation of anticonvulsant medications.
Division of Neurology and Program in Brain and Behavior, Hospital for Sick Children, Department of Pediatrics, Faculty of Medicine, University of Toronto, MSG 1X8 Toronto, Ontario, Canada. elizabeth.donner@sickkids.ca
Elizabeth J
EJ
Donner
O Carter
OC
Snead
D000927:Anticonvulsants / Q000627:therapeutic use*; D002648:Child; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D013678:Technology, Pharmaceutical / Q000639:trends*
D000927:Anticonvulsants